Form 4: Supernus Pharma CMO Reports Equity Changes

Supernus Pharmaceuticals' Chief Medical Officer, Jonathan Rubin, reported changes in his beneficial ownership, including the acquisition of Performance Share Units and shares through an employee plan.

Summary

• Jonathan Rubin, SVP, Chief Medical Officer of Supernus Pharmaceuticals, Inc. (SUPN), reported changes in his beneficial ownership.
• He now directly beneficially owns 9,980 shares of Common Stock.
• This total includes 345 shares acquired through the Issuer's Employee Stock Purchase Plan.
• Rubin acquired 1,875 Performance Share Units (PSUs) on September 10, 2025, which are convertible into an equivalent number of Common Stock shares.
• These PSUs were initially awarded on February 22, 2024, with a portion vesting upon the achievement of individual performance objectives established on June 24, 2024.
• The reported transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The filing indicates routine executive equity compensation and ownership, including performance-based awards and ESPP participation, which are generally positive for aligning executive and shareholder interests. No negative transactions were reported.

Positives

• Acquisition of 1,875 Performance Share Units (PSUs) by a key executive, aligning compensation with company performance objectives.
• Participation in the Employee Stock Purchase Plan (ESPP) for 345 shares, demonstrating executive confidence and investment in the company's equity.

Risks

• The vesting of Performance Share Units is contingent on achieving individual performance objectives, introducing a variable element to the executive's compensation that depends on future performance.

Future Outlook

The vesting of Performance Share Units is tied to future individual performance objectives, indicating ongoing executive incentives aligned with company goals and future performance.

Industry Context

Form 4 filings are standard for reporting insider transactions. The use of Performance Share Units and Employee Stock Purchase Plans are common compensation and incentive mechanisms in the pharmaceutical industry to align executive interests with shareholder value and retain talent.

Comparison to Industry Standards

• The use of Performance Share Units (PSUs) is a common practice in the pharmaceutical and biotech sectors for executive compensation, aligning incentives with long-term company performance and strategic goals, similar to companies like Pfizer or Merck.
• Employee Stock Purchase Plans (ESPPs) are also standard benefits offered by many public companies, including those in the healthcare industry, to encourage employee ownership and commitment.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholder value through equity ownership and performance-based compensation.
• Employees: The Employee Stock Purchase Plan (ESPP) indicates a benefit available to employees, fostering broader employee ownership.

Next Steps

• Future vesting of Performance Share Units will depend on the achievement of individual performance objectives.

Key Dates

Recommendation

This Form 4 filing details routine executive equity compensation and ownership changes, which are not typically a basis for a 'buy' or 'sell' recommendation. The transactions reflect standard incentive structures and executive participation in company equity plans, suggesting alignment of interests but not providing new fundamental information to alter an investment thesis. Therefore, a 'hold' recommendation is appropriate as it does not present new information warranting a change in investment position.

Keywords

Supernus Pharmaceuticals, SUPN, Jonathan Rubin, SVP Chief Medical Officer, Form 4, Insider Trading, Beneficial Ownership, Performance Share Units, Employee Stock Purchase Plan, Equity Compensation, Rule 10b5-1